The Prognostic Value of Leucine-Rich α2 Glycoprotein 1 in Pediatric Spinal Cord Injury

Hong Ma,1 Fengshan Lu,1 Yueming Guo,1 Zhaoxiong Shen,1 and Yuanzhen Chen2

1Foshan Hospital of Traditional Chinese Medicine, Foshan, 528000 Guangdong Province, China
2Neck-Shoulder and Lumbocrural Pain Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250014 Shandong Province, China

Correspondence should be addressed to Yueming Guo; guo_yueming2008@126.com, Zhaoxiong Shen; 591340219@qq.com, and Yuanzhen Chen; chenyuanzhen2011@163.com

Received 21 May 2021; Accepted 26 June 2021; Published 9 July 2021

Academic Editor: Yuzhen Xu

Copyright © 2021 Hong Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Leucine-rich α2 glycoprotein 1 (LRG1) is a novel cytokine, which is believed to be involved in the inflammatory process of a series of diseases. However, the relationship between LRG1 and spinal cord injury (SCI) has not been reported. The purpose of our study is to determine the predictive value of LRG1 for the prognosis of pediatric SCI (PSCI).

Methods. This study recruited 64 patients with confirmed PSCI and 40 healthy controls at Foshan Traditional Chinese Medicine Hospital from January 2016 to December 2020. The clinical information of all participants at the time of admission was recorded. Peripheral blood was collected, and commercial reagents were used to detect the level of serum LRG1. At the same time, the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) was used to assess the severity of PSCI.

Results. All participants were divided into PSCI group (n = 64) and NC group (n = 40). There was no significant difference in clinical information (age, gender, heart rate, systolic blood pressure, diastolic blood pressure, sampling time from injury, white blood cells, and C-reactive protein) between the two groups (p > 0.05). According to the interquartile range of serum LRG1, we compared the motor and sensory scores of ISNCSCI and found that serum LRG1 levels were negatively correlated with the prognosis of PSCI patients (p < 0.001). The results of receiver operating curve (ROC) showed that the sensitivity, specificity, and AUC (Area Under the Curve) of serum LRG1 level in predicting the prognosis of PSCI were 68.4%, 69.1%, and 0.705, respectively. The cut-off value of serum LRG1 level predicting the prognosis of PSCI is 21.1 μg/ml.

Conclusions. Serum LRG1 level is significantly increased in PSCI patients, and the elevated LRG1 level is negatively correlated with the prognosis of PSCI patients. Serum LRG1 may be a potentially useful biomarker for predicting PSCI.

1. Introduction

Spinal cord injury (SCI) can be defined as complete or incomplete damage to motor function, sensory function, autonomic nerves, reflexes, etc. caused by spinal cord structure or function damage [1, 2]. In the United States, there are approximately 17,000 new cases of SCI patients each year, and reports on the incidence of SCI in China range from 25 per million to 60 per million [3, 4]. It is estimated that the total annual cost of SCI in Australia is about 2 billion Australian dollars, and as the life expectancy of SCI patients increases, the economic burden caused by it has becomes heavier [5]. Among children, the incidence of SCI is relatively low, and the reported incidence in the United States is 1.99 per 100,000 [6, 7]. In addition to rehabilitation, there is currently a lack of effective cures for SCI [8]. Therefore, looking for early targets to predict the prognosis of SCI may be of great significance to the prevention and treatment of SCI.

Leucine-rich α-2-glycoprotein 1 is a glycoprotein with a molecular weight of 38-50 kDa encoded by the LRG1 gene [9]. It was first identified in human serum by German scientists Haupt and Baudner in 1977 [10]. LRG1 is composed of 312 amino acid residues, 66 of which are leucine residues. Its leucine-rich repeat sequence family provides a functional domain for protein interaction, which provides the possibility to exert a variety of biological functions in vivo and...
in vitro [11]. LRG1 is widely distributed in the body, and it is reported to be expressed in endothelial cells, neutrophils, macrophages, and hepatocytes [12]. However, in the central nervous system, LRG1 is mainly expressed in the deep cortex, vasculature, and astrocytes, and its expression increases with age [13]. LRG1 is involved in and is increasingly expressed in various physiological reactions, especially inflammation-related reactions [14]. However, the regulation and pathogenic mechanism of LRG1 is not yet fully understood.

In recent years, the role of LRG1 in neurological diseases has been gradually discovered. LRG1 is likely to become a neurobiomarker with clinical application potential. The purpose of our study is to determine whether LRG1 can be used as an indicator for the diagnosis of PSCI. If the correlation between LRG1 and PSCI is confirmed, it will provide a new way for the early diagnosis and effective prevention and treatment of PSCI.

2. Methods

2.1. The Participant. From January 2016 to December 2020, 64 PSCI patients and 40 healthy controls who were treated in Foshan Hospital of Traditional Chinese Medicine were continuously included in the study. The diagnosis of SCI is based on the diagnostic criteria established by the guidelines [15, 16]. The PSCI entry criteria are as follows: (1) age between 6 and 15 years, (2) met the diagnostic criteria of SCI and the onset of SCI within 24 hours, (3) clear consciousness, and (4) stable vital signs. The PSCI exclusion criteria are based on the diagnostic criteria established by the guidelines in Foshan Hospital of Traditional Chinese Medicine were 64 PSCI patients and 40 healthy controls who were treated in Foshan Hospital of Traditional Chinese Medicine. And this study was approved by Foshan Hospital of Traditional Chinese Medicine. And this clinical study complies with the Declaration of Helsinki.

2.2. Clinical Information. Once a participant is enrolled in the group, their clinical information is collected. The clinical information includes age, gender, heart rate, body temperature, and blood pressure. We also collect peripheral blood and use the standard biochemical method of the hospital laboratory to detect the concentration of white blood cells and C-reactive protein. At the same time, we record the time from the patient’s injury to the sample collection.

2.3. Serum LRG1 Concentration. The venous blood of the participants was collected in a serum separation tube (SST) immediately after enrollment. The sample was allowed to clot for 2 hours at room temperature or overnight at 4°C and then centrifuged at 1000 g in a low-temperature centrifuge for 15 minutes. The serum was taken out and used immediately in the experiment. The samples can also be stored in aliquots at -80°C to avoid damage to the samples caused by repeated freezing. Serum LRG1 was detected by enzyme-linked immunosorbent assay (ELISA), and the reagents were purchased from a biological reagent company (Mybioscience, Beverly, MA, USA). For the ELISA test of each serum sample, we take 3 replicate wells. The experimental procedures of ELISA are based on the instructions of the reagents.

2.4. Motor and Sensory Scores of PSCI Patients. The International Standards for Neurological Classification of Spinal Cord Injury (ISNSCI) established by The American Spinal Injury Association (ASIA) is a general standard for evaluating the severity of spinal cord injury [17]. Our study also used this method to evaluate the degree of motor and sensory impairment of PSCI. The total scores of the motor function and sensory scores in ISNSCI are 100 points and 224 points, respectively. The higher the score, the less severe the damage. According to the degree of damage to sensory and motor functions, SCI can be divided into five grades: Grades A, B, C, D, and E. From A to E, Grade A has the heaviest damage and Grade E has the least damage. Each side of the body is scored independently.

2.5. Statistical Analysis. The statistics of the data was obtained using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). The description of continuous variables uses the mean ± standard deviation (SD), and the description of categorical variables uses numbers or percentages (%). The comparison of continuous variables between the two groups uses the t test, while the comparison of categorical variables uses the chi-square test. In the regression model, the trend test of the quartile of serum LRG1 was analyzed by entering the quartile as the ordinal number. The cut-off value of serum LRG1 as a biomarker for the prognosis of PSCI patients was calculated according to Youden’s index. Two-tailed p < 0.05 was used as a statistically significant standard.

3. Results

3.1. The Clinical Information of All Participants. The results of the clinical information of all participants are shown in Table 1. The clinical information includes age, gender, heart rate, body temperature, systolic blood pressure, diastolic
blood pressure, time from injury to sampling, white blood cells, C-reactive protein, and serum LRG1 concentration. The results showed that there was no statistically significant difference between the age, gender, heart rate, body temperature, systolic blood pressure, diastolic blood pressure, time from injury to sampling, white blood cells, and C-reactive protein between the PSCI group and the NC group ($p > 0.05$). The serum LRG1 concentration of the PSCI group and NC group was $18.3 \pm 3.7 \mu g/ml$ and $25.4 \pm 3.2 \mu g/ml$, respectively. The concentration of serum LRG1 in the PSCI group was significantly higher than that in the NC group ($p < 0.001$).

3.2. Relationship between Serum LRG1 and PSCI. According to the serum LRG1 quantile, the ASIA sensory and motor function scores of PSCI patients are shown in Table 2. The results showed that the ASIA sensory and motor function scores of PSCI patients had a linear relationship with the serum LRG1 quantile; that is, the ASIA sensory and motor function scores of PSCI patients decreased with the increase of serum CCL21 levels ($p < 0.001$).

3.3. ROC Curve Analysis. In order to evaluate serum LRG1 as a potential biomarker for the diagnosis of PSCI, we performed receiver operating characteristic (ROC) curve analysis. The ROC curve is shown in Figure 1. The results showed that the sensitivity and specificity of serum LRG1 in diagnosing PSCI were 68.4% and 69.1%, and the area under the curve was 0.705. The diagnostic cut-off value of serum LRG1 calculated using Youden's index was $21.1 \mu g/ml$.

4. Discussions

The main finding of this study is that compared with that in the NC group, the serum LRG1 concentration in the PSCI group was significantly higher, and the serum LRG1 concentration was inversely correlated with the ASIA motor and sensory function scores. Further studies have found that serum LRG1 may be used as an early biomarker for diagnosing the prognosis of PSCI. Our study confirmed for the first time that the serum LRG1 concentration of PSCI patients is correlated with the prognosis of sensory and motor function.

Recent studies have shown that LRG1 is closely related to the pathogenesis of a variety of tumors. Andersen and colleagues found that serum LRG1 levels in patients with ovarian cancer were significantly increased, and it was moderately correlated with the traditional tumor marker CA125 [18]. Kakisaka et al. reported the first increase in plasma LRG1 levels in patients with pancreatic cancer through plasma proteomics technology and verified this new finding through Western blotting [19]. Scholars from China have found that LRG1 is elevated in patients with colorectal cancer and may act as a tumor promoter, which is consistent with the conclusions of Japanese scholars [20, 21]. In addition, the latest research results show that LRG1 can predict the diagnosis and prognosis of glioblastoma, and it has the potential to become a biomarker of glioblastoma [22].

In addition to tumors, the role of LRG1 in immune system diseases and inflammation has gradually gained attention. Serada's team found that LRG concentration is closely related to the disease activity of ulcerative colitis, and its mechanism may involve an IL-6 independent pathway [23]. This result suggests that LRG can be used as a new serum biomarker for monitoring the disease activity of ulcerative colitis.

On this basis, Japanese scholar Shinichiro Shinzaki further concluded that serum LRG can be used as a biomarker for mucosal repair in the course of ulcerative colitis disease activity [24]. LRG not only in peripheral blood but also in saliva can also be used as a noninvasive biomarker.
of airway inflammation in asthma patients [25]. In humans, the serum LRG level of pulmonary tuberculosis patients is significantly increased, but decreased after anti-tuberculosis treatment [26]. These findings indicate that LRG is a promising biomarker for predicting pulmonary tuberculosis activity. A study in South Korea showed that serum LRG may be a new biomarker for evaluating the inflammatory activity of patients with rheumatoid arthritis, and it may be involved in the inflammatory process independently of TNF-α [27]. Unlike the above results, a Brazilian study showed that serum LRG1 cannot be used as a biomarker for the diagnosis of appendicitis [28]. Interestingly, another study on LRG1 and appendicitis in the United States showed that urine LRG1 can distinguish patients with acute appendicitis from patients with nonacute appendicitis [29].

There are also reports on the involvement of LRG1 in neurological diseases. Research from Fukuoka Children’s Hospital shows that LRG1 in cerebrospinal fluid can be used as a potential inflammatory biomarker for meningitis [30]. The research of Juntendo University suggests that the cerebrospinal fluid organism LRG1 may be a potential biomarker for diagnosing idiopathic normal pressure hydrocephalus [31]. The level of LRG1 in the cerebrospinal fluid of patients with Parkinson’s disease combined with dementia (PDD) and progressive supranuclear palsy (PSP) is significantly increased, while the deposition of LRG1 in the cerebral cortex increases with age. Further observation of transgenic mice overexpressing LRG1 can show neuronal degeneration and decline, suggesting that LRG1 is involved in the process of neurodegenerative diseases [32]. Malaysian scholars have found that serum LRG1 levels in patients with severe traumatic brain injury are elevated, suggesting that it can be used as a biomarker for assessing the severity of traumatic brain injury [33]. In addition, LRG1 is also believed to be related to diabetes, myocardial ischemia, and infarction [34, 35]. However, the role of LRG1 in PSCI has not been reported yet.

Our study confirmed for the first time that the serum LRG1 level of PSCI patients is related to the prognosis. Nevertheless, our research has some limitations. First of all, our patients are confined to southern China, and the sample size is small. Secondly, we did not dynamically monitor the level of serum LRG1. Thirdly, we have not done a long-term follow-up study of serum LRG1 and the prognosis of PSCI. Fourthly, we did not detect the level of LRG1 in cerebrospinal fluid. Finally, we did not conduct research on the mechanism of LRG1 involved in the pathogenesis of PSCI.

5. Conclusions

Our research shows that serum LRG1 levels in PSCI patients are significantly increased, which is significantly related to the motor and sensory scores of spinal cord injury. In other words, the more severe the motor and sensory function of spinal cord injury is, the higher the serum LRG1 level. At the same time, serum LRG1 can be used as a biomarker for the diagnosis of PSCI. This conclusion is worthy of our further confirmation and may provide a new way for the treatment of PSCI.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

All the authors declare no conflict of interests.

Authors’ Contributions

Yueming Guo, Zhaoxiong Shen, and Yuanzhen Chen are the corresponding authors.

References

[1] Y. Chen, L. Liang, S. Cao et al., “Serum CCL21 as a potential biomarker for cognitive impairment in spinal cord injury,” BioMed Research International, vol. 2020, Article ID 6692802, 5 pages, 2020.
[2] N. Wang, Y. Yang, M. Pang et al., “MicroRNA-135a-5p promotes the functional recovery of spinal cord injury by targeting SP1 and rock,” Molecular Therapy - Nucleic Acids, vol. 22, pp. 1063–1077, 2020.
[3] S. Yuan, Z. Shi, F. Cao, J. Li, and S. Feng, “Epidemiological features of spinal cord injury in China: a systematic review,” Frontiers in Neurology, vol. 9, p. 683, 2018.
[4] Y. Chen, D. Wang, S. Cao, G. Hou, H. Ma, and B. Shi, “Association between serum IL-37 and spinal cord injury: a prospective observational study,” BioMed Research International, vol. 2020, Article ID 6664313, 5 pages, 2020.
[5] B. P. Vaikuntam, J. W. Middleton, P. McElduff et al., “Identifying predictors of higher acute care costs for patients with traumatic spinal cord injury and modeling acute care pathway redesign: a record linkage study,” Spine, vol. 44, no. 16, pp. E974–E983, 2019.
[6] H. Darain, A. Arsh, A. Zeb, S. Muhammad Ilyas, D. Muhammad, and M. Naseem Khan, “Epidemiology, clinical features and consequences of spinal cord injury in children,” Journal of the College of Physicians and Surgeons–Pakistan : JCPSP, vol. 28, no. 7, pp. 532–535, 2018.
[7] K. Zebracki, M. Hwang, P. L. Patt, and L. C. Vogel, “Autonomic cardiovascular dysfunction and vitamin D deficiency in pediatric spinal cord injury,” Journal of Pediatric Rehabilitation Medicine, vol. 6, no. 1, pp. 45–52, 2013.
[8] N. Wang, L. He, Y. Yang et al., “Integrated analysis of competing endogenous RNA (ceRNA) networks in subacute stage of spinal cord injury,” Gene, vol. 726, p. 144171, 2020.
[9] C. Akiba, M. Nakajima, M. Miyajima et al., “Leucine-rich α2-glycoprotein overexpression in the brain contributes to memory impairment,” Neurobiology of Aging, vol. 60, pp. 11–19, 2017.
[10] H. Haupt and S. Baudner, ”Isolierung und charakterisierung eines bisher unbekannten leucinreichen 3.1S-α2-Glykoproteins aus humanserum,” Hoppe-Seyler’s Zeitschrift fur physiologische Chemie, vol. 358, no. 1, pp. 639–646, 1977.
[11] Y. Yang, R. Luo, Y. Cheng et al., “Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis,” BMC Nephrology, vol. 21, no. 1, p. 122, 2020.
[12] L. J. Druhan, A. Lance, S. Li et al., “Leucine rich α-2 glycoprotein: a novel neutrophil granule protein and modulator of myelopoiesis,” PLoS One, vol. 12, no. 1, article e0170261, 2017.
[13] M. Nakajima, M. Miyajima, I. Ogino et al., "Brain localization of leucine-rich α2-glycoprotein and its role," Acta Neurochirurgica. Supplement, vol. 113, pp. 97–101, 2012.

[14] T. Otsuru, S. Kobayashi, H. Wada et al., "Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoprotein," Cancer Science, vol. 110, no. 3, pp. 985–996, 2019.

[15] B. C. Walters, M. N. Hadley, R. J. Hurlbert et al., "Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update," Neurosurgery, vol. 60, CN, Supplement 1, pp. 82–91, 2013.

[16] M. G. Fehlings, L. A. Tetreault, J. R. Wilson et al., "A clinical practice guideline for the management of patients with acute spinal cord injury and central cord syndrome: recommendations on the timing (≤24 hours versus >24 hours) of decompressive surgery," Global Spine Journal, vol. 7, Supplement 3, pp. 195S–202S, 2017.

[17] M. J. Mulcahey, J. Gaughan, R. R. Betz, and K. Johansen, "The international standards for neurological classification of spinal cord injury: reliability of data when applied to children and youths," Spinal Cord, vol. 45, no. 6, pp. 452–459, 2007.

[18] J. D. Andersen, K. L. Boylan, R. Jemmerson et al., "Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients," Journal of Ovarian Research, vol. 3, no. 1, p. 21, 2010.

[19] T. Kakisaka, T. Kondo, T. Okano et al., "Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer," Analytical Technologies in Biomedical and Life Sciences, vol. 852, no. 1-2, pp. 257–267, 2007.

[20] Q. Zhang, R. Huang, Q. Tang et al., "Leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter," Oncotargets and Therapy, vol. 11, pp. 2745–2752, 2018.

[21] E. Shinozaki, K. Tanabe, T. Akiyoshi et al., "Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker," BMC Cancer, vol. 18, no. 1, p. 406, 2018.

[22] T. Furuta, Y. Sugita, S. Komaki et al., "The multipotential of leucine-rich α2 glycoprotein 1 as a clinicopathological biomarker of glioblastoma," Journal of Neuropathology and Experimental Neurology, vol. 79, no. 8, pp. 873–879, 2020.

[23] S. Serada, M. Fujimoto, F. Terabe et al., "Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis," Inflammatory Bowel Diseases, vol. 18, no. 11, pp. 2169–2179, 2012.

[24] S. Shinzaki, K. Matsuoka, H. Iijima et al., "Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis," Journal of Crohn’s & Colitis, vol. 11, no. 1, pp. 84–91, 2017.

[25] H. Honda, M. Fujimoto, S. Miyamoto et al., "Sputum leucine-rich alpha-2 glycoprotein as a marker of airway inflammation in asthma," PLoS One, vol. 11, no. 9, article e0162672, 2016.

[26] M. Fujimoto, T. Matsumoto, S. Serada et al., "Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis," Scientific Reports, vol. 10, pp. 1–10, 2020.

[27] Y. J. Ha, E.-J. Kang, S.-W. Lee et al., "Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity bio-marker in patients with rheumatoid arthritis," Journal of Korean Medical Science, vol. 29, no. 9, pp. 1199–1204, 2014.

[28] M. B. Lontra, R. F. Savaris, L. T. Cavazzola, and J. Maissiat, "Comparison of leucine-rich alpha-2-glycoprotein-1 (LRG-1) plasma levels between patients with and without appendicitis, a case–controlled study," Scientific Reports, vol. 11, pp. 1–5, 2021.

[29] A. Kentsis, S. Ahmed, K. Kurek et al., "Detection and diagnostic value of urine leucine-rich α-2-glycoprotein in children with suspected acute appendicitis," Annals of Emergency Medicine, vol. 60, no. 1, pp. 78–83.e1, 2012.

[30] P. F. Chong, Y. Sakai, H. Torisu et al., "Leucine-rich alpha-2 glycoprotein in the cerebrospinal fluid is a potential inflammatory biomarker for meningitis," Journal of the Neurological Sciences, vol. 392, pp. 51–55, 2018.

[31] M. Nakajima, M. Miyajima, I. Ogino et al., "Leucine-rich α2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus," Acta Neurochirurgica, vol. 153, no. 6, pp. 1339–1346, 2011.

[32] M. Miyajima, M. Nakajima, Y. Motoi et al., "Leucine-rich α2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex," PLoS One, vol. 8, no. 9, article e74453, 2013.

[33] R. P. Anada, K. T. Wong, J. J. Jayapalan, O. H. Hashim, and D. Ganesan, "Panel of serum protein biomarkers to grade the severity of traumatic brain injury," Electrophoresis, vol. 39, no. 18, pp. 2308–2315, 2018.

[34] J.-J. Liu, S. L. Pek, J. Wang et al., "Association of plasma leucine-rich α-2 glycoprotein 1, a modulator of transforming growth factor-β signaling pathway, with incident heart failure in individuals with type 2 diabetes," Diabetes Care, vol. 44, no. 2, pp. 571–577, 2021.

[35] C. Xuan, H. Li, L. L. Li et al., "Screening and identification of pregnancy zone protein and leucine-rich alpha-2-glycoprotein as potential serum biomarkers for early-onset myocardial infarction using protein profile analysis," Proteomics–Clinical Applications, vol. 13, no. 3, article 1800079, 2019.